Glenmark Pharmaceuticals’ arm completes Phase I trial of GRC 15300

25 Jul 2011 Evaluate

Glenmark Pharmaceuticals’ subsidiary - Glenmark Pharmaceuticals SA (GPSA) has successfully completed the Phase I trial of GRC 15300, a first-in-class TRPV3 inhibitor for treatment of pain.

GRC 15300 is an inhibitor of the TRPV3 (transient receptor potential cation channel, subfamily V, member 3). This is the first TRPV3 inhibitor which entered clinical trials. Glenmark has completed phase I dosing and analysis of the study data of GRC 15300 in the UK and the drug has been well tolerated with a good pharmacokinetic profile.

Glenmark Pharmaceuticals registered growth of 65.17% in its net profit after tax for the year ended March 31, 2011 at Rs 212.18 crore as compared to Rs 128.46 crore for the previous year. Its total income has increased by 19.43% at Rs 1185.02 crore for the year under review from Rs 992.22 crore in previous year.

Glenmark Pharma Share Price

1622.40 -13.65 (-0.83%)
06-Jan-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1846.95
Dr. Reddys Lab 1350.65
Cipla 1490.55
Lupin 2357.75
Zydus Lifesciences 961.75
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.